Capricor says FDA inspection brought Form 483 with several observations

12-06-2025

Capricor Therapeutics (CAPR) announced the completion of the Food and Drug Administration's pre-license inspection of its San Diego manufacturing facility for Deramiocel, the company's lead cell therapy candidate with a biologics license application under FDA review for potential approval in the treatment of Duchenne muscular dystrophy. The inspection concluded with a Form 483 containing several observations. Capricor said it has submitted its responses to the FDA, none of which required material changes to the cGMP process or facility. 'The observations were primarily related to routine quality systems and documentation practices. The Company is confident that the facility will meet the necessary requirements to support product licensure and, pending approval, commercial launch,' Capricor added. The FDA informed Capricor of its intent to hold the Advisory Committee meeting on July 30, although that date is pending confirmation by the FDA. 'At the time of the mid-cycle review, no significant issues or major deficiencies were noted. A late-cycle meeting is planned for mid-July 2025,' the company added. The BLA for Deramiocel remains under priority review with a Prescription Drug User Fee Act action date of August 31.
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today's best-performing stocks on TipRanks >>
Read More on CAPR:
Disclaimer & DisclosureReport an Issue
Largest borrow rate increases among liquid names
Capricor Therapeutics participates in a conference call with Maxim
Capricor Therapeutics Approves 2025 Equity Incentive Plan
MongoDB and Asana downgraded: Wall Street's top analyst calls
Capricor Therapeutics initiated with a Buy at Roth Capital

Hashtags

#PrescriptionDrugUserFeeAct

#CapricorTherapeutics

#FDA

#Capricor

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Capricor Therapeutics Stock (CAPR) Plummets 40% on FDA Rejection

Business Insider

2 hours ago

Business Insider

Capricor Therapeutics Stock (CAPR) Plummets 40% on FDA Rejection

Capricor Therapeutics (CAPR) stock dove on Friday after the biotechnology company revealed a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). This letter covered its Biologics License Application (BLA) for Deramiocel, a cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). That's a severe genetic disorder that causes progressive muscle weakness and degeneration. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. The big news here is that the FDA completed its review of the BLA for Deramiocel and has rejected the therapy in its current form. The FDA said it 'does not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data.' The FDA is willing to restart its review with additional data and has granted Capricor Therapeutics a Type A meeting to discuss further action. Capricor Therapeutics CEO Linda Marbán noted that the CRL from the FDA was a surprise. She claimed that the company followed the FDA's guidance throughout the submission process and that no issues were revealed ahead of the CRL. She said the company will 'submit data from the Phase 3 HOPE-3 clinical trial to provide additional evidence of effectiveness from an adequate and well-controlled study.' Capricor Therapeutics Stock Movement Today CAPR stock was down 38.51% in pre-market trading on Friday, following a slight 0.18% dip yesterday. The shares were also down 17.39% year to date, but remained up 159.09% over the past 12 months. Today's news triggered a stock selloff, with some 4 million shares traded this morning, compared to a three-month daily average of about 2.59 million units. Is Capricor Therapeutics Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Capricor Therapeutics is Strong Buy, based on nine Buy and one Hold rating over the past three months. With that comes an average CAPR stock price target of $30.60, representing a potential 167.42% upside for the shares.

FDA New Leadership, US Farming Economics, Corporate Breakups

Bloomberg

4 hours ago

Bloomberg

FDA New Leadership, US Farming Economics, Corporate Breakups

This week, the FDA's new commissioner Dr. Marty Makary outlines a new approach to the department, hoping to restore public trust. Plus, checking in on the heartland of the US - we travel to Iowa to see how much American farmers rely on export markets. Later, a look at the ever-evolving media landscape and whether mergers and breakups have actually helped the challenged industry. (Source: Bloomberg)

Ultragenyx falls 4% to $28.41 after FDA rejection letter for gene therapy

Business Insider

5 hours ago

Business Insider

Ultragenyx falls 4% to $28.41 after FDA rejection letter for gene therapy

17:19 EDT Ultragenyx (RARE) falls 4% to $28.41 after FDA rejection letter for gene therapy Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>